Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Purpose:

To evaluate the efficacy when administering steroid combined with single dose rituximab to eliminate the antibody in acquired hemophilia A patients compared to treatment using steroid with cyclophosphamide.

The study will test the hypothesis that steroid combined with small dose rituximab is as effective as steroid combined with cyclophosphamide for FVIII inhibitor eradication in Chinese patients with acquired hemophilia A.

Study design Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhang Lei
• Collaborators: Henan Cancer Hospital; Qilu Hospital of Shandong University; The Second Affiliated Hospital of Kunming Medical University; Tianjin First Central Hospital
• Treatments: Cyclophosphamide; Rituximab

Criteria

Inclusion Criteria:

• 18-80 years old

• Men or women

• Women post-menopausal or with ongoing contraception

• Diagnosis of acquired hemophilia A

• Patient must be insured

• Patient has provided written informed consent prior to enrollment

• Patient compliant

Exclusion Criteria:

• Congenital hemophilia

• Ongoing treatment with prednisone > 20mg/d （or equivalent corticosteroid doses） more than 1 month

• Ongoing treatment with prednisone >0.7mg/kg（or equivalent corticosteroid doses） more than 10 days

• Pregnant and breastfeeding women

• Allergy to steroid

• Immunosuppressive agents treatment within 30 days

• Serum transaminase and bilirubin greater than 1.5 times the upper limit of normal value

• Hepatitis B surface antigen or hepatitis C antibody or HIV antibody (I + II) or syphilis antibody positive

• Patients with diabetes, hypertension, glaucoma, peptic ulcer, herpes zoster, pulmonary infection and so on, who should not be treated with glucocorticoids

• Patients with poor compliance

• Those who can not take contraceptive measures during the test period

• Patient who is considered by the investigator not suitable for clinical study

• Thrombocytopenia

• Leucocytopenia